We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > bipolar disorder

News List

OWP Announces IND Approval for Quetiapine Fumarate Liquid Oral Suspension Formulation americanpharmaceuticalreview
October 10, 2020
OWP has received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the first-ever liquid formulation of quetiapine fumarate.
OWP Announces Pre-IND Acknowledgement, Patent Application for Schizophrenia, Bipolar Disorder Treatment americanpharmaceuticalreview
January 13, 2020
OWP Pharmaceuticals has received Pre-Investigational New Drug (PIND) acknowledgement from the U.S. Food and Drug Administration (FDA), and has submitted for U.S. patent protection, for the first-ever liquid formulation of quetiapine fumarate.
Could the Family Dog Lower a Child's Odds for Schizophrenia Later? drugs
January 02, 2020
You might just want to throw Fido a few extra bones for the holidays, as new research suggests that growing up with a dog may lower schizophrenia risk by as much as 24%.
Gene breakthrough on lithium treatment for bipolar disorder europeanpharmaceuticalreview
November 09, 2017
According to international research led by the University of Adelaide, The reason for psychiatric patients don’t respond to the gold standard treatment for bipolar the drug lithium is...